Robert Marcus
Stock Analyst at JP Morgan
(1.49)
# 3,537
Out of 5,149 analysts
24
Total ratings
55.56%
Success rate
-0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $175 | $174.21 | +0.45% | 11 | Feb 10, 2026 | |
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $340.16 | +8.77% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $10.56 | +610.23% | 2 | Dec 17, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $117.75 | -57.54% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $148.00 | -89.86% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $31.46 | +81.18% | 2 | Jul 29, 2020 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $175
Current: $174.21
Upside: +0.45%
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $340.16
Upside: +8.77%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $10.56
Upside: +610.23%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $117.75
Upside: -57.54%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $148.00
Upside: -89.86%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $31.46
Upside: +81.18%